Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

CGene Tech of Suzhou Raises $14.5 Million in Series A+ Round to Develop Small-Molecule Drugs

publication date: Aug 2, 2019

CGene Tech, a Suzhou BioBay novel small molecule drug developer, raised $14.5 million in a Series A+ financing, led by Hongtai Capital with ABC International participating. CGene's lead candidate is an innovative cetagliptin phosphate DPP-4 inhibitor for type 2 diabetes that has completed a Phase I trial in China. CGene said it would use the proceeds from the round to advance the clinical program for its hypoglycemic drug and support development of its oncology candidates and generic drugs for rare diseases. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China